Core Points - Morgan Stanley reduced its stake in Kelaiying (06821) by 202,000 shares at a price of HKD 83.432 per share, totaling approximately HKD 16.8533 million [1] - After the reduction, Morgan Stanley's remaining shareholding is approximately 2.0432 million shares, representing a holding percentage of 7.41% [1]

Investment Rating - The report maintains a "Market Weight" rating for the pharmaceutical and biotechnology industry, indicating that the industry is expected to perform within ±10% of the market index over the next six months [3][29]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 0.61% from October 24 to November 6, 2025, which is approximately 2.50 percentage points lower than the index [10][23]. - Most sub-sectors within the industry recorded negative returns during the same period, with the vaccine and pharmaceutical distribution sectors showing the highest gains of 2.87% and 2.33%, respectively, while offline pharmacies and medical research outsourcing experienced declines of 3.95% and 3.11% [11][12]. - Approximately 57% of stocks in the industry recorded positive returns, with notable performers including Hezhong China, which saw a weekly increase of 115.96% [15][12]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry lagged behind the CSI 300 index, with a decline of 0.61% from October 24 to November 6, 2025 [10]. - Most sub-sectors recorded negative returns, with vaccines and pharmaceutical distribution leading in gains [11]. - About 57% of stocks in the industry had positive returns, with significant fluctuations among individual stocks [15]. 2. Industry News - The 11th batch of national drug centralized procurement results was announced, involving 55 varieties and 445 companies, with a selection rate of 57% [21]. - The new procurement rules emphasize clinical stability, quality assurance, and higher standards for bidding companies [21]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received approval for clinical trials of YKYY013 injection for chronic hepatitis B treatment [22]. 4. Industry Outlook - The report suggests focusing on investment opportunities in innovative drugs and sectors with expected business development catalysts, including medical devices and traditional Chinese medicine [25]. - Key companies to watch include Mindray Medical, Yifeng Pharmacy, and Aier Eye Hospital, among others [26].

Group 1: Company Performance and Earnings - Sanhe Construction Group (03822) surged over 70% after announcing a profit increase to at least HKD 40 million for the six months ending September 30, 2025, compared to HKD 3 million in the same period last year, driven by efficient project execution and final account settlements [1] - Yidu International Holdings (00259) rose over 7.76% as it expects a profit of approximately HKD 1.2 billion for the six months ending September 30, 2025, up from HKD 89 million in the previous year, primarily due to fair value changes in its equity stake in Nantong Jianghai Capacitor Co., Ltd. [2] - Kailaiying (06821) increased over 2.22% with a reported revenue growth of 11.82% for the first three quarters of 2025, expecting a full-year revenue growth of 13%-15% [3] Group 2: Market Trends and Sector Performance - Longpan Technology (02465) rose over 8% as demand for lithium hexafluorophosphate and lithium iron phosphate surged due to downstream operations, indicating a positive industry outlook [1] - Greenview China Real Estate (00095) increased over 20% after completing several financing adjustments that alleviated financial pressure and improved liquidity [2] - Dongyue Group (00189) rose over 7.05% amid a surge in the organic silicon sector, with reports of major polysilicon companies planning to form a consortium to eliminate excess capacity [4] Group 3: Stock Market Movements - China Gas (00384) rose over 3% as Beijing prepares for a new heating season with dropping temperatures [1] - Snap Inc (SNAP.US) increased over 9.73% after reporting a 10% revenue growth to USD 1.51 billion in Q3, slightly exceeding analyst expectations [8] - AstraZeneca (AZN.US) rose over 3.23% with a reported 12% revenue growth to USD 15.191 billion in Q3, benefiting from strong sales of key cancer and diabetes drugs [8]

Core Viewpoint - Kailaiying (06821) has seen a stock price increase of over 3%, currently at 85.8 HKD, with a trading volume of 13.68 million HKD. The company reported a revenue of 4.63 billion CNY for the first three quarters of 2025, reflecting an 11.82% year-on-year increase, and a net profit of 800 million CNY, up 12.66% year-on-year. The company anticipates a significant increase in delivery scale in Q4 compared to Q3, projecting an overall revenue growth of 13%-15% for the year [1][1][1]. Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 4.63 billion CNY, which is an 11.82% increase year-on-year [1]. - The net profit attributable to shareholders was 800 million CNY, marking a 12.66% year-on-year increase [1]. - The basic earnings per share stood at 2.18 CNY [1]. Business Segments - The small molecule CDMO business, a cornerstone of Kailaiying, reported revenue that remained flat year-on-year, with a gross margin of 47.0%, down 1.9 percentage points [1]. - Emerging business segments showed strong growth, with a revenue increase of 71.9% year-on-year and a gross margin of 30.6%, up 10.6 percentage points [1]. - The revenue from the chemical macromolecule business grew by over 150% year-on-year [1]. Market Outlook - The company is actively expanding its market presence in emerging business areas such as peptides, oligonucleotides, and ADC, with new orders maintaining double-digit growth [1]. - The expansion of production capacity is expected to position emerging business segments as a core growth engine for the company [1].

Core Viewpoint - Kailaiying (002821) reported a revenue increase of 11.82% year-on-year for the first three quarters of 2025, reaching 4.63 billion yuan, with a net profit of 800 million yuan, reflecting a 12.66% increase [1] Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 4.63 billion yuan, up 11.82% year-on-year [1] - The net profit attributable to shareholders was 800 million yuan, representing a 12.66% increase [1] - Basic earnings per share stood at 2.18 yuan [1] Future Outlook - The company anticipates that the delivery scale in the fourth quarter will significantly exceed that of the third quarter, projecting an annual revenue growth of 13%-15% [1] Business Segments - The small molecule CDMO business revenue remained stable year-on-year, with a gross margin of 47.0%, down 1.9 percentage points [1] - Emerging business segments showed strong growth, with a revenue increase of 71.9% year-on-year and a gross margin of 30.6%, up 10.6 percentage points [1] - The chemical macromolecule business saw revenue growth exceeding 150% year-on-year [1] Order Growth - The company is actively expanding its market presence in emerging business areas such as peptides, oligonucleotides, and ADC, maintaining double-digit growth in new orders [1] - Coupled with capacity expansion, emerging businesses are expected to become a core growth engine for the company [1]

Macro and Strategy - The macroeconomic environment shows a recovery in upstream sectors, while midstream sectors exhibit a mixed recovery, with the coal industry maintaining stability and the petrochemical sector continuing to face challenges [9] - The manufacturing sector, particularly in the new energy chain, is showing improvement, with demand for machinery and automotive sectors gradually recovering [9] - Consumer sectors are experiencing a divergence, with home appliances and food and beverage sectors showing positive trends, while the pharmaceutical sector faces increasing price pressures [9] Industry and Company Analysis Textile and Apparel Industry - Adidas reported a 12% increase in revenue for Q3 2025, with management raising the full-year guidance due to strong brand momentum and better-than-expected performance [10][11] - The company achieved a net profit of €485 million in Q3, with all regions and channels showing double-digit growth, except for North America, which was impacted by a decline in accessory sales [10][11] - The management has adjusted the full-year revenue growth expectation to approximately 9%, with an operating profit target raised to about €2 billion [10][11] Agricultural Chemicals Industry - The potassium fertilizer market is experiencing a tight supply-demand balance, with domestic production expected to decrease by 2.7% in 2024, while imports are projected to increase by 9.1% [12][13] - The average price of potassium chloride in October was reported at ¥3228 per ton, reflecting a year-on-year increase of 28.3% [12] - The demand for lithium iron phosphate is rising, with production capacity reaching 5.92 million tons per year, and prices increasing by 7% in October [13] Livestock and Agriculture - The investment strategy for November 2025 recommends focusing on Hong Kong-listed dairy farming stocks, with expectations for beef prices to accelerate [17] - The report highlights a potential turning point in the domestic beef cycle, with optimism for both domestic and international markets [17] - The prices of live pigs and poultry are showing upward trends, with live pig prices increasing by 6% month-on-month [18] Medical Devices - Mindray Medical's international business is growing steadily, with Q3 revenue expected to accelerate compared to Q2 [26] - The company reported a revenue of ¥258.34 billion for the first three quarters of 2025, with a net profit of ¥75.70 billion, despite facing price pressures in the domestic market [26][27] - The company is focusing on enhancing its global supply chain and local production capabilities, with international revenue accounting for over 50% of total revenue [26] Pharmaceutical Industry - The report on Baicheng Pharmaceutical indicates a significant decline in revenue and net profit for the first three quarters of 2025, attributed to intensified competition in the generic drug market [28][29] - The company is transitioning towards innovative drug development, with over 15 projects in the pipeline, focusing on neurology, autoimmune diseases, and oncology [29] - The production capacity utilization is expected to improve as the company secures contracts for multiple drug varieties [29] Orthopedic Devices - Weigao Orthopedics reported a 10% increase in revenue for Q3 2025, driven by sales model integration and refined management practices [31] - The company is focusing on optimizing its sales structure and enhancing clinical service levels, which has led to increased revenue and volume across multiple product lines [31][32] - The net profit margin has improved significantly, reflecting effective cost control and operational efficiency [32]

Group 1 - Norges Bank increased its stake in Kailaiying (06821.HK) by purchasing 62,300 shares at an average price of HKD 84.5083 per share, amounting to approximately HKD 5.265 million [1][2] - Following this transaction, Norges Bank's total shareholding in Kailaiying rose to 3,888,300 shares, increasing its ownership percentage from 13.89% to 14.11% [1][2]

Core Insights - Norges Bank increased its stake in Kelaiying (002821)(06821) by acquiring 62,300 shares at a price of HKD 84.5083 per share, totaling approximately HKD 5.2649 million [1] - Following this transaction, Norges Bank's total shareholding in Kelaiying reached 3.8883 million shares, representing a 14.11% ownership stake [1]

Core Insights - Norges Bank increased its stake in Kairong (06821) by acquiring 62,300 shares at a price of HKD 84.5083 per share, totaling approximately HKD 5.2649 million [1] - Following this acquisition, Norges Bank's total shareholding in Kairong reached 3.8883 million shares, representing a 14.11% ownership stake [1]

Investment Rating - The investment rating for the company is "Outperform the Market" [5][3][20] Core Views - The company achieved steady growth in the first three quarters of 2025, with revenue reaching 4.63 billion yuan (+11.82%) and net profit attributable to shareholders at 800 million yuan (+12.66%) [1][6] - Emerging businesses are becoming the core growth engine, with a significant increase in revenue from new business areas, particularly in chemical macromolecules, which saw over 150% growth [2][3] - The company is expected to maintain rapid revenue growth throughout 2025, with projected revenues of 6.68 billion yuan, 7.53 billion yuan, and 8.29 billion yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 15%, 13%, and 10% [3][4] Financial Performance Summary - For the first three quarters of 2025, the company reported quarterly revenues of 1.54 billion yuan, 1.65 billion yuan, and 1.44 billion yuan for Q1, Q2, and Q3 respectively, with Q2 showing the highest growth at +26.95% [1][6] - The operating cash flow improved to 1.144 billion yuan (+8.38%), indicating enhanced operational efficiency and effective cost control [2][12] - The gross margin for the small molecule CDMO business was 47.0% (-1.9pp), while the emerging business gross margin was 30.6% (+10.6pp) [2][3] Earnings Forecast - The company forecasts net profits of 1.14 billion yuan, 1.29 billion yuan, and 1.46 billion yuan for 2025, 2026, and 2027 respectively, with expected growth rates of 20%, 14%, and 14% [3][4] - The current price-to-earnings ratio (PE) is projected to be 29.8, 26.3, and 23.1 for the years 2025, 2026, and 2027 respectively [3][4]